*Rule 3.19A.2*

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available.*
*Information and documents given to ASX become ASX's property and may be made public.*

**Introduced 30/9/2001. Amended 01/01/11**

| | |
|---|---|
| **Name of Entity:** | **Antisense Therapeutics Limited** (ASX:ANP) |
| **ABN:** | 41 095 060 745 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|---|---|
| **Name of Director:** | Mr Robert W Moses |
| **Date of Last Notice:** | 5th December 2016 |

### Part 1 – Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Direct or Indirect Interest** | Direct |
| **Nature of indirect interest (including registered holder)**<br>Note: Provide details of the circumstances giving rise to the relevant interest. | N/A |
| **Date of change** | 19th December 2016 |
| **No. of securities held prior to change** | |
| **Class** | Options |
| **Number acquired** | |
| **Number disposed** | |

**No. of securities held prior to change**

| | Shares | Options |
|---|---|---|
| **Direct** | 3,554,434 | 708,001 |
| **Indirect** | - | |
| **Total** | **3,554,434** | **708,001** |

**Number acquired**

| | Shares | Options |
|---|---|---|
| **Direct** | | 1,418,888 |
| **Indirect** | - | - |
| **Total** | | 1,418,888 |

**Number disposed**

| | Shares | Options |
|---|---|---|
| **Direct** | - | - |
| **Indirect** | - | - |
| **Total** | - | - |

+ See chapter 19 for defined terms.

| | |
|---|---|
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and estimated valuation | Bonus Option Allocation – Nil Consideration<br>Participation in New Option Offer - $1,416 |
| **No. of securities held after change** | |
| **Nature of change**<br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Bonus Option Allocation<br>Participation in New Option Offer to Eligible Optionholders |

| | **Shares** | **Options** |
|---|---|---|
| **Direct** | 3,554,434 | 2,126,889 |
| **Indirect** | - | |
| **Total** | **3,554,434** | **2,126,889** |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Detail of contract** | N/A |
| **Nature of interest** | N/A |
| **Name of registered holder (if issued securities)** | N/A |
| **Date of change** | N/A |
| **No. and class of securities to which interest related prior to change**<br>Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| **Interest acquired** | N/A |
| **Interest disposed** | N/A |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| **Interest after change** | N/A |

## Part 3 – Closed period

| | |
|---|---|
| **Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?** | No |
| **If so, was prior written clearance provided to allow the trade to proceed during this period?** | N/A |
| **If prior written clearance was provided, on what date was this provided?** | N/A |

*Rule 3.19A.2*

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available.*
*Information and documents given to ASX become ASX's property and may be made public.*

**Introduced 30/9/2001. Amended 01/01/11**

| | |
|---|---|
| **Name of Entity:** | **Antisense Therapeutics Limited** (ASX:ANP) |
| **ABN:** | 41 095 060 745 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|---|---|
| **Name of Director:** | Mr Mark Diamond |
| **Date of Last Notice:** | 21st October 2015 |

**Part 1 – Change of director's relevant interests in securities**
*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Direct or Indirect Interest** | Direct |
| **Nature of indirect interest (including registered holder)**<br>Note: Provide details of the circumstances giving rise to the relevant interest. | - |
| **Date of change** | 19th December 2016 |
| **No. of securities held prior to change** | <table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td>1,457,914</td><td>351,189</td></tr><tr><td>**Indirect**</td><td>-</td><td>-</td></tr><tr><td>**Total**</td><td>**1,457,914**</td><td>**351,189**</td></tr></table> |
| **Class** | Options |
| **Number acquired** | <table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td>-</td><td>642,772</td></tr><tr><td>**Indirect**</td><td>-</td><td>-</td></tr><tr><td>**Total**</td><td>-</td><td>642,772</td></tr></table> |

+ See chapter 19 for defined terms.

| | |
|---|---|
| **Number disposed** | <table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td>-</td><td>-</td></tr><tr><td>**Indirect**</td><td>-</td><td>-</td></tr><tr><td>**Total**</td><td>-</td><td>-</td></tr></table> |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and estimated valuation | Bonus Option Allocation – Nil Consideration<br>Participation in New Option Offer - $702.38 |
| **No. of securities held after change** | <table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td>1,457,914</td><td>993,961</td></tr><tr><td>**Indirect**</td><td>-</td><td>-</td></tr><tr><td>**Total**</td><td>**1,457,914**</td><td>**993,961**</td></tr></table> |
| **Nature of change**<br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Bonus Option Allocation<br>Participation in New Option Offer to Eligible Optionholders |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Detail of contract** | N/A |
| **Nature of interest** | N/A |
| **Name of registered holder (if issued securities)** | N/A |
| **Date of change** | N/A |
| **No. and class of securities to which interest related prior to change**<br>Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| **Interest acquired** | N/A |
| **Interest disposed** | N/A |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| **Interest after change** | N/A |

## Part 3 – Closed period

| | |
|---|---|
| **Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?** | No |
| **If so, was prior written clearance provided to allow the trade to proceed during this period?** | N/A |
| **If prior written clearance was provided, on what date was this provided?** | N/A |

*Rule 3.19A.2*

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available.*
*Information and documents given to ASX become ASX's property and may be made public.*

**Introduced 30/9/2001. Amended 01/01/11**

| | |
|---|---|
| **Name of Entity:** | **Antisense Therapeutics Limited** (ASX:ANP) |
| **ABN:** | 41 095 060 745 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|---|---|
| **Name of Director:** | Dr Graham Mitchell |
| **Date of Last Notice:** | 12 November 2014 |

**Part 1 – Change of director's relevant interests in securities**
*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Direct or Indirect Interest** | Direct |
| **Nature of indirect interest (including registered holder)**<br>Note: Provide details of the circumstances giving rise to the relevant interest. | - |
| **Date of change** | 19th December 2016 |
| **No. of securities held prior to change** | **Shares** / **Options**<br>**Direct** 240,180 / 60,582<br>**Indirect** - / -<br>**Total** **240,180** / **60,582** |
| **Class** | Ordinary Shares<br>Options |
| **Number acquired** | **Shares** / **Options**<br>**Direct** 24,000 / 48,036<br>**Indirect** / -<br>**Total** **24,000** / 48,036 |

+ See chapter 19 for defined terms.

| | |
|---|---|
| **Number disposed** | <table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td>-</td><td>24,000</td></tr><tr><td>**Indirect**</td><td>-</td><td>-</td></tr><tr><td>**Total**</td><td>-</td><td>**24,000**</td></tr></table> |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and estimated valuation | Exercise of zero price options<br>Bonus Option Allocation |
| **No. of securities held after change** | <table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td>264,180</td><td>84,618</td></tr><tr><td>**Indirect**</td><td>-</td><td></td></tr><tr><td>**Total**</td><td>**264,180**</td><td>**84,618**</td></tr></table> |
| **Nature of change**<br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Exercise of options<br>Issue of bonus options. |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Detail of contract** | N/A |
| **Nature of interest** | N/A |
| **Name of registered holder (if issued securities)** | N/A |
| **Date of change** | N/A |
| **No. and class of securities to which interest related prior to change**<br>Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| **Interest acquired** | N/A |
| **Interest disposed** | N/A |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| **Interest after change** | N/A |

## Part 3 – Closed period

| | |
|---|---|
| **Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?** | No |
| **If so, was prior written clearance provided to allow the trade to proceed during this period?** | N/A |
| **If prior written clearance was provided, on what date was this provided?** | N/A |

*Rule 3.19A.2*

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

**Introduced 30/9/2001. Amended 01/01/11**

| | |
|---|---|
| **Name of Entity:** | Antisense Therapeutics Limited |
| **ABN:** | 41 095 060 745 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|---|---|
| **Name of Director:** | William Goolsbee |
| **Date of Last Notice:** | 19th October 2016 |

**Part 1 - Change of director's relevant interests in securities**
*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Direct or Indirect Interest** | Direct |
| **Nature of indirect interest (including registered holder)**<br>Note: Provide details of the circumstances giving rise to the relevant interest. | |
| **Date of change** | 19th December 2016 |
| **No. of securities held prior to change** | **Shares** / **Options**<br>**Direct** 422,000- / -<br>**Indirect** - / -<br>**Total** 422,000- / - |
| **Class** | Options |
| **Number acquired** | **Shares** / **Options**<br>**Direct** / 84,400<br>**Indirect** /<br>**Total** / 84,400 |
| **Number disposed** | **Shares** / **Options**<br>**Direct** - / -<br>**Indirect** - / -<br>**Total** - / - |

+ See chapter 19 for defined terms.

| | |
|---|---|
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and estimated valuation | Nil consideration |
| **No. of securities held after change** | <table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td>422,000</td><td>84,400</td></tr><tr><td>**Indirect**</td><td>-</td><td>-</td></tr><tr><td>**Total**</td><td>422,000</td><td>84,400</td></tr></table> |
| **Nature of change**<br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Bonus Option Allocation |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Detail of contract** | N/A |
| **Nature of interest** | N/A |
| **Name of registered holder (if issued securities)** | N/A |
| **Date of change** | N/A |
| **No. and class of securities to which interest related prior to change**<br>Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| **Interest acquired** | N/A |
| **Interest disposed** | N/A |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| **Interest after change** | N/A |

**Part 3 – +Closed period**

| | |
|---|---|
| **Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?** | No |
| **If so, was prior written clearance provided to allow the trade to proceed during this period?** | N/A |
| **If prior written clearance was provided, on what date was this provided?** | N/A |



+ See chapter 19 for defined terms.